Stéphane BancelChief Executive Officer & Director, Moderna, Inc. (MRNA)
5 recorded appearances
Bancel and Merck's Dean Li presented the first positive late-stage results for their individualised mRNA cancer vaccine, and argued the shot combined with Keytruda could become a new melanoma treatment option.
A French-language interview on Moderna's pipeline and strategy.
Bancel revisited his 2011 decision to leave a 6,000-person diagnostics company for a ~50-person startup built on an idea most scientists thought had roughly a 5% chance of working, and what that says about risk-taking in biotech leadership.
Bancel argued the striking feature of the individualised neoantigen therapy data is durability of effect, and sized the potential commercial opportunity.
Bancel argued the one-size-fits-all model of medicine is breaking, using mRNA's speed in COVID, rare genetic disease and individualised cancer treatment as evidence that manufacturing personalised medicines at scale is now tractable.